Together, these results imply that targeting upstream regulators such as DOCK2 and downstream effectors, such as IQGAP1, could be effective therapeutic strategies for counteracting RAC1P29S-mediated melanoma progression and resistance to targeted therapies. Here, DOCK2 is linked to melanoma.